title: The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease.
abstract: OBJECTIVE
  Combined infliximab and sphincter-sparing surgery can be effective in perianal fistula associated with Crohn's disease (CD). This study aimed to assess the efficacy of local surgery combined with infliximab on sustained fistula closure and to identify predictive factors for response after this combined treatment.
  
  
  METHODS
  Between 2000 and 2010, 81 patients with fistulising perianal CD were included in this observational study. Drainage with a loose seton was followed by infliximab therapy. The primary end-points were the rate of complete fistula closure and time required for this to occur.
  
  
  RESULTS
  The fistula was complex in 71 (88%) of the 81 patients. Local proctological surgery was carried out in 77 (95%), including seton drainage in 62 (80.5%) of these. This was continued for a median duration of 3.8 months and the patient then received infliximab therapy. The median follow-up after treatment was 64 months (2-263). Initial complete closure of the fistula occurred in 71 (88%) cases at a median interval of 12.4 months (1-147) from the start of treatment. Recurrence was observed in 29 (41%) patients at a median interval of 38.5 months (2-48) from the start of treatment. They were treated again with combined treatment with successful closure in 19 (65.5%) patients. The total rate of closure of the fistula was 75.3%. Female gender, anal stenosis, rectovaginal and complex fistula formation were factors independently associated with failure of combined treatment.
  
  
  CONCLUSIONS
  Seton drainage for several months combined with infliximab therapy is effective in closing the fistula in 75% of patients with complex perianal fistula formation associated with CD.
authors.affiliation: Department of Gastroenterology, Hôpital Rangueil, University of Toulouse, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Haennig
authors.forename: G
authors.initials: G
authors.lastname: Staumont
authors.forename: B
authors.initials: B
authors.lastname: Lepage
authors.forename: P
authors.initials: P
authors.lastname: Faure
authors.forename: L
authors.initials: L
authors.lastname: Alric
authors.forename: L
authors.initials: L
authors.lastname: Buscail
authors.forename: B
authors.initials: B
authors.lastname: Bournet
authors.forename: J
authors.initials: J
authors.lastname: Moreau
mesh_terms: D000293:Adolescent; D000328:Adult; D001003:Anal Canal; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications / Q000628:therapy*; D004322:Drainage / Q000379:methods; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D059351:Organ Sparing Treatments; D012003:Rectal Fistula / Q000209:etiology / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Crohn's disease; infliximab; perianal fistula; setons